HMG‐CoA reductase inhibition protects the diabetic myocardium from ischemia‐reperfusion injury

This publication has 32 references indexed in Scilit:

• Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels
  Circulation, 1998
• Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
  New England Journal of Medicine, 1998
• Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS)
  Circulation, 1998
• Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?
  The Lancet, 1996
• Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia
  The American Journal of Medicine, 1995
• A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non—Insulin-dependent diabetes mellitus and hyperlipoproteinemia
  Metabolism, 1995
• Beneficial Effects of Cholesterol-Lowering Therapy on the Coronary Endothelium in Patients with Coronary Artery Disease
  New England Journal of Medicine, 1995
• Influence of diabetes on mortality in acute myocardial infarction: Data from the GISSI-2 study
  Journal of the American College of Cardiology, 1993
• The Impact of Diabetes on Survival Following Myocardial Infarction in Men vs Women
  JAMA, 1988
• Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study
  Diabetes, 1974